IPA-3

Research use only, not for human use.

IPA-3 is a selective non-ATP competitive Pak1 inhibitor with IC50 of 2.5 μM, no inhibition to group II PAKs (PAKs 4-6).

IPA-3 is a potent and selective PAK1 inhibitor. IPA-3 inhibits the growth of liver cancer cells by suppressing PAK1 and NF-κB activation. IPA-3 treatment significantly inhibited the growth of HCC cells. The mechanisms through which IPA-3 treatment suppresses HCC cell growth are enhancement of apoptosis and blockage of activation of NF-κB. IPA-3 not only inhibits the HCC cell growth, but also suppresses the metastatic potential of HCC cells. Nude mouse xenograft assay demonstrated that IPA-3 treatment significantly reduced the tumor growth rate and decreased tumor volume, indicating that IPA-3 can suppress the in vivo tumor growth of HCC cells. Hepatocellular carcinoma (HCC) is one of the major malignancies worldwide and is associated with poor prognosis due to the high incidences of metastasis and tumor recurrence. Overexpression of p21-activated protein kinase 1 (PAK1) is frequently observed in HCC and is associated with a more aggressive tumor behavior, suggesting that PAK1 is a potential therapeutic target in HCC.

IPA-3; IPA 3; IPA3

Others

Other Targets

PAK1

Cancer

——

42521-82-4

350.45

C20H14O2S2

98%

DMSO : ≥ 100 mg/mL 285.35 mM; H2O : < 0.1 mg/mL

OC1=CC=C2C=CC=CC2=C1SSC1=C2C=CC=CC2=CC=C1O

1,1'-disulfanediylbis(naphthalen-2-ol)

(-20℃)

With Ice Pack

≥ 2 years